An Ohio State hematologist discusses a new trial comparing tovorafenib plus rituximab with standard cladribine-based treatment, and what quality of life means for patients.
An Ohio State hematologist explains how she weighs chemotherapy against targeted drugs, what side effects patients should expect and why learning about this specific leukemia matters.